



Supplementary Figure-1: ACR20 response rates through Week 52 in TNFi-naïve and TNFi-exposed patients



* $P < 0.0001$; † $P < 0.001$; § $P < 0.01$; ‡ $P < 0.05$ vs. placebo

Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52
 ACR, American College of Rheumatology; s.c., subcutaneous; TNFi, tumor necrosis factor inhibitor

Supplementary Figure-2: ACR20 response rates in TNFi-naïve and TNFi-exposed patients with or without concomitant MTX




†P < 0.001; §P < 0.01; ‡P < 0.05 vs. placebo

Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52


ACR, American College of Rheumatology; MTX, methotrexate; s.c., subcutaneous; TNFi, tumor necrosis factor inhibitor

Supplementary Figure-3: ACR20 response rates in TNFi-naïve and TNFi-exposed patients stratified by body weight



*P < 0.0001; †P < 0.001; §P < 0.01; ‡P < 0.05 vs. placebo
 Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52
 ACR, American College of Rheumatology; s.c., subcutaneous; TNFi, tumor necrosis factor inhibitor

Supplementary Figure-4: ACR20 response rates in TNFi-naïve and TNFi-exposed patients stratified by baseline disease activity



* $P < 0.0001$; § $P < 0.01$; ‡ $P < 0.05$ vs. placebo

Missing values were imputed as non-response (non-responder imputation) at Weeks 24 and 52

ACR, American College of Rheumatology; DAS28-CRP, 28-joint Disease Activity Score using C-Reactive Protein; s.c., subcutaneous; TNFi, tumor necrosis factor inhibitor